Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Rigano A., Sturlese E.*, Rigano M.*, Baviera G.**
From the Department of Endocrinological Gynecology, *Department of Obstetric and Ginecology, ** Department of Clinical Biochemistry University of Messina, Italy
Background. Purpose of the study was to investigate changes in the hormonal pattern in postmenopausal women after high- dose danazol therapy. In 16 postmenopausal women (mean age 66.4±8.6) treated with danazol 1.2 g/die ×21 we studied serum levels, before and after therapy, of FSH, LH, E2, fE2, T, fT, D4-A, DHEAS, SHBG.
Methods. FSH, LH, SHBG by IRMA kits (DPC); E2, T, DHEAS, D4-A by RIA kits (Sorin Biomedica) after celite microcolumn chromatography; fT by coat-A-count kit (DPC); fE2 by equilibrium dialysis; serum albumin by bromocresol-green colorimetric method.
Results. After therapy there was a statistically significant decrease of LH by 13%, of FSH by 19%, SHBG by 84% and increase of fE2 by 24.5%, fT by 77%. Other hormones show changes that are not statistically significant.
Conclusions. In postmenopausal women danozol therapy, even if at a higher dose, has about same effect on hormonal pattern as in normally cycling women. Danazol showed a clear antigonadotropic effect and can play a role in therapy when reduction of gonadotrophins and E2 secretion is desirable.